Use of the dopamine receptor agonist Mirapex in the treatment of Parkinson's disease

Neuroscience and Behavioral Physiology

Volumn 37, Issue 6, 2007, Pages 539-546

  Fedorova, N V ^a,b   Chigir', I P ^a,b  

^a Federal Agency for Health Care and Social Development   (Russian Federation)

^b N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

Dopamine receptor agonists; Mirapex; Parkinson's disease; Treatment

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CABSAR; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; LEVODOPA; LISENIL; LISURIDE; PERGOLIDE; PERGOLIDE MESILATE; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; PRONORAN; ROPINIROLE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ANXIETY; AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE DURATION; DISEASE SEVERITY; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSKINESIA; GASTROINTESTINAL SYMPTOM; GENERAL CONDITION; HALLUCINATION; HUMAN; MONOTHERAPY; MOTOR ACTIVITY; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; QUALITY OF LIFE; REVIEW;

ACTIVITIES OF DAILY LIVING; AGED; ANXIETY; BENZOTHIAZOLES; DEPRESSION; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; REVIEW LITERATURE; TIME FACTORS;

EID: 34548253983     PISSN: 00970549     EISSN: 1573899X     Source Type: Journal    
DOI: 10.1007/s11055-007-0050-3     Document Type: Review

References (59)

1. V. L. Golubev, Ya. I. Levin, and A. M. Vein, Parkinson's Disease and Parkinsonism Syndrome [in Russian], MEDpress, Moscow (1999).
2. M. R. Nodel', D. V. Artem'ev, and N. N. Yakhno, "The efficacy of the dopamine agonist Mirapex in Parkinson's disease," Nevrol. Zh., 4, 45-49 (1999).
3. N. V. Fedorova and V. N. Shtok, "Strategy and tactics in the treatment of Parkinson's disease," Konsilium, 3, No. 5, 237-242 (2001).
4. V. N. Shtok and N. V. Fedorova, The Treatment of Parkinsonism [in Russian], Moscow (1997).
5. V. N. Shtok and N. V. Fedorova, "Current concepts in the treatment of parkinsonism," Rus. Med. Zh., 6, No. 13, 837-844 (1998).
6. N. N. Yakhno, "Current approaches to the treatment of Parkinson's disease," Klin. Farmakol. Ter. No. 3-4, 92-97 (1994).
7. P. Carvey, S. Pieri, and Z. Ling, "Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole," J. Neural Transm., 104, 209-228 (1997).
8. J. M. Cedarbaum, "Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease," Neurol. Clin., 8, 31-49 (1990).
9. T. N. Chase and J. F. Oh, "Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications," Ann. Neurol., 47, Supplement 1, 122-129 (2000).
10. G. Cohen, "Oxygen radicals and Parkinson's disease," in: Oxygen Radicals and Tissue Injury. B. Halliwell (ed.) (1988), pp. 130-135.
11. 4 receptors expressed in Chinese hamster ovary cells," Brit. J. Pharmacol., 127, No. 7, 1696-1702 (1999).
12. M. H. Corrigan, A. Q. Denahan, C. E. Wright, and R. J. Ragual, "Comparison of pramipexole, fluoxetine, and placebo in patients with major depression," Depress. Anxiety, 11, 58-65 (2000).
13. S. Fahn, "Adverse effects of levodopa," in: The Scientific Basis for the Treatment of Parkinson's Disease, C. W. Olanow and A. N. Lieberman (eds.), Carnforth, UK (1992), pp. 89-112.
14. S. T. Gancher, "Pharmacology of Parkinson's disease," in: Parkinson's Disease, S. J. Huber and J. L. Cummings (eds.), New York (1992), pp. 273-287.
15. C. G. Goetz, "Dopaminergic agonists in the treatment of Parkinson's disease," Neurology, 40, Supplement 3, 50-54 (1990).
16. M. Guttman, "Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease," Neurology, 49, Supplement 4, 1060-1065 (1997).
17. R. G. Holloway, "The Parkinson Study Group. Pramipexole versus levodopa as initial treatment for Parkinson's disease: A four-year randomized controlled trial," Neurology, 58, 81-82 (2000).
18. J. P. Hubble, W. C. Koller, N. R. Cutler, et al., "Pramipexole in patients with early Parkinson's disease," Clin. Neuropharmacol., 18, No. 4, 338-347 (1995).
19. M. Kreider and S. Knox, "A multicenter double-blind study of ropinirole as an adjunct to l-dopa in Parkinson's disease [abstract]," Neurology, 46, Supplement, 475 (1996).
20. A. E. Lang, "Are the new dopamine agonists better than the old ones?" in: Sixth International Congress of Parkinson's Disease and Movement Disorders, Barcelona (2000).
21. A. Lieberman, S. Imke, M. Muenter, et al., "Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa," Neurology, 43, 1981-1984 (1993).
22. A. Lieberman, A. Ranhosky, and D. Korts, "Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study," Neurology, 49, No. 1, 162-168 (1997).
23. G. Linazasoro, "On behalf of Spanish Dopamine Agonists Study Group. Conversion from dopamine agonists to pramipexole," J. Neurol., 251, 335-339 (2004).
24. C. D. Marsden, "The mysteries of motor function of the basal ganglia: The Robert Wartenburg lecture," Neurology, 32, 514-539 (1982).
25. C. D. Marsden, "Parkinson's disease," J. Neurol. Neurosurg. Psychiat., 57, 672-681 (1994).
26. E. S. Molho, S. A. Factor, W. J. Weiner, et al., "The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease," J. Neural. Transm., 45, Supplement, 225-230 (1995).
27. D. Nyholm, H. Lennernas, C. Trolin, et al., "Plasma levodopa concentrations in parkinsonian patients during activities of daily living," in: The Movement Disorder Society's 6th International Congress of Parkinson's Disease and Movement Disorders, Barcelona (2000).
28. N. Ogawa, I. Miyazaki, K. Tanaka, et al., "Dopamine D 2 receptor mediated antioxidant and neuroprotective effects of ropinirole," in: XIII International Congress on Parkinson's Disease, Vancouver (1999).
29. C. W. Olanow, "Oxidation reactions in Parkinson's disease," Neurology, 40 Supplement 3, 32-37 (1990).
30. C. W. Olanow, "A rationale for dopamine agonists as primary therapy for Parkinson's disease," Can. J. Neurol. Sci., 19, 108-112 (1992).
31. J. D. Parkes, N. Schachter, C. D. Marsden, et al., "Lisuride in parkinsonism," Ann. Neurol., 9, 48-52 (1981).
32. "Parkinson Study Group. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism," Neurology, 55, 1540 (2000).
33. "Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: Design and methods of the CALM-PD study," J. Clin. Neuropharmacol., 23, No. 1, 34-44 (2000).
34. H. L. Paulson and M. B. Stern, Movement Disorders: Neurologic Principles and Practice, New York (1997), pp. 183-199.
35. M. F. Piercey, W. E. Hoffmann, M. W. Smith, et al., "Inhibition of dopamine neuron firing by pramipexole, a dopamine D, receptor-preferring agonist: Comparison to other dopamine receptor agonists," Eur. J. Pharmacol., 312, No. 1, 35-44 (1996).
36. M. M. Pinter, O. Pogarell, and W. H. Ortel, "Efficacy, safety and tolerance of non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double-blind, placebo controlled, randomized, multicentre study," J. Neurol. Neurosurg. Psychiat., 66, No. 4, 436-441 (1999).
37. W. H. Poewe and G. K. Kenning, "The natural history of Parkinson's disease," Ann. Neurol., 44, Supplement 1, 1-9 (1998).
38. O. Pogarell, T. Gasser, J. J. van Hilten, et al., "Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: A randomized double-blind, placebo controlled, multicentre study," J. Neurol. Neurosurg. Psychiat., 72, No. 6, 713-720 (2002).
39. R. M. Post, R. H. Gerner, J. S. Carman, et al., "Effects of dopamine agonist piribedil in depressed patients: Relationship of pre-treatment homovanillic acid to antidepressant response," Arch. Gen. Psychiat., 35, No. 5, 609-615 (1978).
40. N. Quinn, "Drug treatment of Parkinson's disease," Brit. Med. J., 310, Supplement 6979, 575-579 (1995).
41. A. H. Rajput, "Adverse effects of ergot-derivative dopamine agonists," in: Dopamine Agonists in Early Parkinson's Disease, C. W. Olanow and J. E. Obeso (eds.), Kent, UK (1997), pp. 209-216.
42. O. A. Rascol, "A double blind l-dopa controlled study of ropinirole patients with early Parkinson's disease," Neurology, 46, Supplement, 139 (1996).
43. H. Reichmann, H. M. Brecht, P. J. Kraus, et al., "Pramipexole in Parkinson's disease. Results of a treatment observation," Nervenarzt, 73, No. 8, 745-750 (2002).
44. U. K. Rinne, "Early dopamine agonist treatment in Parkinson's disease," Tn: Parkinson's Disease: the Role of Dopamine Agonists, A. Lieberman and X. Lataste (eds.), Lanes (1989), pp. 29-33.
45. U. K. Rinne, "A five year double blind study with cabergoline versus levodopa in the treatment of early Parkinson's disease," in: XIII International Congress on Parkinson's Disease, Vancouver (1999).
46. 2 receptors," NeuroReport, 6, No. 2, 329-332 (1995).
47. M. Schroder, A. Kühn, and A. Kupsch, "Impaired tonic vigilance associated with pramipexole," in: Sixth International Congress of Parkinson's Disease and Movement Disorders, Barcelona (2000).
48. K. M. Shannon, J. P. Bennett, and J. H. Friedman, "Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group," Neurology, 49, No. 724-728 (1997).
49. R. P. Snaith, M. Hamilton, S. Morley, et al., "A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale," Brit. J. Psychiat., 167, No. 1, 99-103 (1995).
50. W. G. Tatton, W. Y. H. Ju, J. Wadia, et al., "Reduction of neuronal apoptosis by small molecules: Promise for new approaches to neurological therapy," in: Neurodegeneration and Neuroprotection in Parkinson's Disease, C. W. Olanow, P. Jenner, and M. H. B. Youim (eds.), London (1996), pp. 202-220.
51. "The Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease. A randomized dose-ranging study," J. Am. Med. Assoc., 278, No. 2, 125-130 (1997).
52. "The Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease: A randomized controlled trial," J. Am. Med. Assoc., 284, No. 15, 1931-1938 (2000).
53. J. Waehrens and J. Gerlach, "Bromocriptine and imipramine in endogenous depression: A double-blind controlled trial in out-patients," J. Affect. Disord., 3, No. 2, 193-202 (1981).
54. W. J. Wiener and A. E. Lang, Movement Disorders: A Comprehensive Survey, Mount. Kisco, New York (1989).
55. L. Wermuth, "A double-blind, placebo-controlled, randomized, multicenter study of pramipexole in advanced Parkinson's disease," Eur. J. Neurol., 5, No. 3, 235-242 (1998).
56. E. C. Wolters, G. Tissingh, P. L. M. Bergmans, et al., "Dopamine agonists in Parkinson's disease," Neurology, 45, Supplement 3, 28-34 (1995).
57. G. F. Wooten, "Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease," Ann. Neurol., 24, 363-365 (1988).
58. A. Zenzola, C. Diroma, A. Fraddosio, et al., Efficacy and Tolerability of Dopamine Agonists in a Parkinsonian Population, Bar (2000).
59. M. Ziegler and P. Rondor, "Activity of piribedil in Parkinson's disease: A multicenter study," Presse Med., 28, 1414-1418 (1999).